Key facts
- This page summarizes Michael Cordonnier's Form 4 filing for CARLSMED, INC. (CARL).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 04 Mar 2026, 16:05.
Michael Cordonnier - 02 Mar 2026 Form 4 Insider Report for CARLSMED, INC. (CARL)
- Reporting relationship
- CEO, President, Director
- Issuer ticker
- CARL
- Reported as of
- 02 Mar 2026
- Net transaction value
- -$2,629,889
- SEC form
- 4
- Accepted by SEC
- 04 Mar 2026, 16:05:03 UTC
- Prior SEC filing
- 30 Jan 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael Cordonnier
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Michael Cordonnier filed Form 4 for CARLSMED, INC. (CARL) on 04 Mar 2026.
Change
- Previous filing in this sequence was filed on 30 Jan 2026.
- Current net transaction value: -$2,629,889.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002077087
Primary reporting owner
Cordonnier Michael
- Relationship
- CEO, President, Director
- Address
- C/O CARLSMED, INC., 1800 ASTON AVE., SUITE 100, CARLSBAD
- Signature
- /s/ Michael Cordonnier
- Signature date
- 04 Mar 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CARL
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +197,855
- Change %
- +15%
- Price
- $0.3350*
- Shares after
- 1,554,501
- Date
- 02 Mar 2026
- Ownership
- Direct
CARL
transaction
Common Stock
Sale
- Transaction value
- $2,629,889
- Shares
- -197,855
- Change %
- -13%
- Price
- $13.29
- Shares after
- 1,356,646
- Date
- 02 Mar 2026
- Ownership
- Direct
- Footnotes
- F1, F2
CARL
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +160,567
- Change %
- +12%
- Price
- $0.3350*
- Shares after
- 1,517,213
- Date
- 03 Mar 2026
- Ownership
- Direct
CARL
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +33,264
- Change %
- +2.2%
- Price
- $4.35*
- Shares after
- 1,550,477
- Date
- 03 Mar 2026
- Ownership
- Direct
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CARL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -197,855
- Change %
- -55%
- Price
- $0.000000*
- Shares after
- 160,567
- Date
- 02 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 197,855
- Exercise price
- $0.3350
- Footnotes
- F3
CARL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -160,567
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 03 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 160,567
- Exercise price
- $0.3350
- Footnotes
- F3
CARL
transaction
Derivative
Stock Option (Right to Buy)
Options Exercise
- Transaction value
- Shares
- -33,264
- Change %
- -15%
- Price
- $0.000000*
- Shares after
- 191,692
- Date
- 03 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 33,264
- Exercise price
- $4.35
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Sale of shares to cover the exercise price, withholding tax obligations and broker fees and commissions, pursuant to a broker assisted cashless exercise of vested stock options granted on January 8, 2021 and February 19, 2025 under the Carlsmed, Inc. 2019 Stock Incentive Plan.
Footnote F2
This transaction was executed in multiple trades at prices ranging from $13.000 to $14.030. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request, to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
Footnote F3
25% of the shares underlying these options, representing a right to purchase a total of 358,422 shares, vested and became exercisable on December 15, 2021, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
Footnote F4
25% of the shares underlying these options, representing a right to purchase a total of 224,956 shares, vested and became exercisable on December 15, 2025, with the remaining shares vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.